Why we measure it

CEA is primarily used in clinical oncology for post-surgical monitoring of known colorectal cancer — a rising CEA after curative resection is an early indicator of recurrence, often detectable months before imaging reveals disease. In the context of an annual health protocol for a presumably healthy individual, CEA serves a different but complementary purpose: establishing a personal baseline and detecting sustained or progressive upward trends that warrant further investigation. A CEA that rises from 1.2 to 2.1 to 3.8 ng/mL over three consecutive annual draws — each individually 'normal' — is a signal that a rising CEA alone would not convey without the longitudinal context. CEA is most informative when interpreted alongside CA 19-9 and AFP: a combined elevation across multiple gastrointestinal tumour markers substantially raises the pre-test probability for occult GI malignancy and warrants colonoscopy, CT imaging, or specialist review. CEA is not a substitute for colonoscopy as colorectal cancer screening — it is a complementary blood-based signal.

Why every 12 months

Annual testing is the appropriate cadence for CEA in a health surveillance context. More frequent testing raises false-positive anxiety without improving sensitivity for clinically significant disease; less frequent testing reduces the trend data needed for meaningful interpretation. A sustained CEA above the reference range on two consecutive annual draws — particularly in the absence of known benign causes — warrants clinical investigation.

What movement means

The upper reference limit for CEA is typically 2.5 ng/mL for non-smokers and approximately 5.0 ng/mL for smokers, though laboratory-specific ranges vary. The trend and the rate of rise — not the absolute level — are the most clinically informative features in a surveillance context.

In the protocol